Bicuspid aortic valve and aortic aneurysm: timing and lifetime treatment strategy based on age and anatomy
Prof. D’Onofrio
Aortic Highlights course
Prof. Borger
Aortic Highlights course, 2023
Prof. Doenst
Edwards Lifesciences at EACTS 2022: State of the art in the treatment of aortic valve regurgitation in young patients
Prof. Ruggero De Paulis
MVT Aortic 2022, vol.1
– First and foremost, not all bicuspid aortic valves are the same
– Many post-operative measurements and goals are included within to help guide you to optimal patient outcomes
– Check out the insight provided about valve-sparing, valve repair, external annuloplasty, and more
Prof. Marjan Jahangiri
MVT Aortic 2022, vol.1
– Shorter time to extubation, shorter length of stay, shorter hospital stays
– Pre-operative strategies to enhance post-operative and follow-up outcomes
– Don’t forget to pay attention to the intra-operative details and work with the entire Heart Team for optimal patient outcomes
Prof. Augusto d’Onofrio
MVT Aortic 2022, vol.1
– Valve-in-valve, TAVI in TAVI, SAVR after TAVI… familiarize yourself with the mid-to-long-term data for each valve type combination, and transparently inform the patients of not only the benefits but also the risks
– Even the experts say, extracting an infected TAVI is extremely difficult, so be sure to choose the original valve wisely
Prof. Hanneke Takkenberg – EACTS 2021
Edwards Lifesciences Symposium
Patients are at the core of the new ESC/EACTS guidelines. The recommendation for patient-focused decision making covers all therapeutic areas.
Key points include:
Informed patient choice is crucial
Patient life expectancy and quality of life should be considered
Patient-centred evaluation is at the heart of ensuring informed treatment choice is offered to patients
Prosthetic valve selection should be made during Heart Team evaluation, and with consideration of the patient’s preferences
The patient-centred approach
Patient-centred decision making should be made by a fully collaborative Heart Team, right from clinical evaluation, imaging assessment through to intervention selection. Learn more about the importance of the Heart Team here.
All pieces of the puzzle need to fit together, to understand patient preferences and robustly diagnose and evaluate each patient, in order to come to a joint decision on treatment choice.
Prosthetic valve selection
To ensure the right treatment for each patient, every time, your patient should be given the opportunity to make an informed choice, and any decisions should be made in close collaboration with the Heart Team.
Involve your patients when it comes to:
- Understanding their lifestyle, any impact of anti-coagulation or the possibility of future re-do surgical, or transcatheter surgery
- Informing them of the influence of age in valve selection, particularly where life expectancy is less than bioprosthesis durability
- How valve selection will impact quality of life, whether this is an impact on diet or return to active lifestyle
- Understanding the potential risks and benefits of any potential intervention
The guidelines give a clear recommendation on when tissue valves should be selected, find out more here.
Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.
© 2021 Edwards Lifesciences Corporation. All rights reserved. PP–EU-3125 v1.0
Edwards Lifesciences • Route de l’Etraz 70, 1260 Nyon, Switzerland • edwards.com
The highly anticipated 2021 European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) guidelines for the management of valvular heart disease have finally landed.
We are excited to bring you a summary of the main updates, plus the new materials coming soon to support you and your teams in understanding and implementing the changes.
Key points include:
Treatment recommendations for all patients with severe aortic stenosis to be made by the Heart Team
Intervention options for patients with asymptomatic aortic stenosis
Bioprosthetic valves now recommended for those with life expectancy shorter than valve durability
Intervention recommended for patients with secondary mitral regurgitation, who remain symptomatic despite guideline-directed medical therapy
Use your experience of severe aortic stenosis to ensure the best patient outcomes
The choice between surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation (TAVI) must be made following evaluation of all factors – clinical, anatomical and procedural – weighing the risks and benefits of each approach for all patients with severe aortic stenosis, and after discussion with the patient.
Treatment options have broadened for patients with asymptomatic aortic stenosis, including those with systolic left ventricular (LV) dysfunction (LV ejection fraction <55%) without another cause.
Enable more of your patients to live the active lifestyle they desire
Bioprosthetic valves now have a Class I recommendation for patients with life expectancy lower than the durability of the valve. Now, more of your patients can live a life free from anticoagulation. In addition, bioprosthetic valves may be considered for patients already on long-term novel oral anticoagulants.
Ensure you meet your patients’ high expectations by offering them the best valve technologies.
Be courageous, be experienced, be ethical… according to the guidelines!
Join us from the comfort of your office for a virtual symposium discussing the changes and what they mean for your practice. Eleven speakers from across Europe will cover the implications for the aortic, mitral and tricuspid valves. Click here for the full programme.
Tuesday 21 September 2021
3.00–7.45 pm CET
REGISTER NOW
Coming soon from Edwards
Edwards, Edwards Lifesciences, and the stylized E logo are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.
© 2021 Edwards Lifesciences Corporation. All rights reserved. NP–EU-0633 v1.0
Edwards Lifesciences • Route de l’Etraz 70, 1260 Nyon, Switzerland • edwards.com
Dr. Gianluigi Perri
MVT Aortic 2021
Dr. Torsten Christ, Germany
Dr. Marco Di Eusanio
What to know in 2020
Keywords: aortic stenosis; aortic valve replacement; patient–prosthesis mismatch; rapid-deployment aortic valves
Severe aortic stenosis in low- and intermediate-risk patients is currently treated by surgical aortic valve replacement (SAVR). However, SAVR can cause patient–prosthesis mismatch (PPM), a condition where a patient’s body surface area is too big compared with the effective orifice area of the implant. This mismatch results in higher transvalvular pressure gradients and is associated with a higher risk of adverse outcomes. There is a potential risk of PPM in patients who undergo SAVR due to higher transvalvular pressure gradients, especially if they have a small aortic root.
Coti et al. studied patients with a small aortic root who underwent SAVR with the EDWARDS INTUITY valve. This single-centre cohort analysis provides useful insights by analysing haemodynamic parameters, survival rates, functional class improvements and PPM incidence.
Click on the link below to see the outcomes of the EDWARDS INTUITY valve transplant in at-risk patients.
Click here to access the full publication
Important safety information:
Use of the EDWARDS INTUITY Elite valve system may be associated with new or worsened conduction disturbances, which may require a permanent cardiac pacemaker implant (PPI). The rate of PPI for the EDWARDS INTUITY Elite valve is within the range reported in the literature for various rapid deployment valves, but higher than that reported for surgical aortic valves. Physicians should assess the benefits and risks of the EDWARDS INTUITY Elite valve prior to implantation. See instructions for use for additional information.
For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).
Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.
Edwards, Edwards Lifesciences, the stylized E logo, Carpentier-Edwards, EDWARDS INTUITY, and EDWARDS INTUITY Elite are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.
© 2020 Edwards Lifesciences Corporation. All rights reserved.
Edwards Lifesciences • Route de l’Etraz 70, 1260 Nyon, Switzerland • edwards.com
